Cibus streamlines focus on Rice weed traits, targets $30M annual cash burn by 2026

Cibus, Inc.

Focusing on HT1 and HT3 herbicide tolerance traits in Rice for commercial launch in Latin America (2027-2028) and U.S. mid-south (2028).
Plans cost reductions to reduce annual net cash burn to ~$30M by 2026, including rationalizing headcount and non-core facilities.
Regulatory wins: California approval for gene-edited Rice field research (Feb 2025); USDA-APHIS designated two Canola traits as not regulated (Apr 2025).
Ecuador determined HT1/HT3 Rice traits equivalent to conventional breeding (Apr 2025), important as country prohibits GMO planting.
Partner-funded sustainable ingredients program targeting nominal revenues in 2025 with commercial expansion in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.